A 12-week randomized, double-blind, placebo-controlled phase 3 trial of the efficacy and safety of appetite suppressant, new formulation of pentermine 30mg diffuse controlled release in the treatment of korean obese patients

Authors
Category Primary study
JournalDiabetes
Year 2009
This article has no abstract
Epistemonikos ID: 09a560045dee680049b126a79f0583892b0ac012
First added on: Feb 28, 2025